Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Rituximab 23Cyclophosphamide 21Prednisone 16Doxorubicin 14Magnetic Resonance Spectroscopy 13Vincristine 11Specimen Handling 11Lenalidomide 10ibrutinib 8Biopsy 8obinutuzumab 7polatuzumab vedotin 6glofitamab 6Gemcitabine 6Oxaliplatin 5venetoclax 4prednylidene 4pembrolizumab 4fludarabine 4deltacortene 4Prednisolone 4Etoposide 4Dexamethasone 4Cyclosporine 4CT-P10 4fludarabine phosphate 3Whole-Body Irradiation 3R-CHOP protocol 3Nivolumab 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × ibritumomab tiuxetan × 30 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡